US30161Q1040 - Common Stock
22 +0.01 (+0.05%)
After market: 22 0 (0%)
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END
/PRNewswire/ -- USA News Group - According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this...
Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL.
Will EXELIXIS INC breakout?
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
EXEL earnings call for the period ending September 30, 2023.
Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high.
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END
/PRNewswire/ -- The R&D for cancer vaccines has been growing in the last few years and is projected to continue through the next decade. A cancer vaccine is...
Exelixis (EXEL) reported positive Phase 3 results for its drug Cabometyx in the treatment of certain neuroendocrine tumors. Read more here.
These three lesser-known biotech companies are profitable and growing revenue.
There is one key reason to consider the stock.
Low-beta stocks provide an avenue for investors looking for long-term growth accompanied by low volatility.
H.C. Wainwright initiates Exelixis with a buy rating, citing its robust pipeline of targeted oncology assets. Read more here.
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.
A 14% decline in the Nasdaq Composite represents the perfect opportunity for investors to pounce.